Purchase Order HHSN261201800151P

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic for $64,050.00 on August 22, 2016, for enrollment of women at increased risk of endometrial cancer, with an ultimate completion date of March 25, 2021. Work is performed at Mayo Clinic's facility in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The award involved de-obligation of funds from expiring FY2016 lines.</p>

The National Cancer Institute issued a $167,149.99 delivery order to Mayo Clinic on August 7, 2017, under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients parent IDIQ for pharmacokinetic and bioavailability studies of selected anticancer compounds in mice and pharmacological evaluations of agents in development for cancer patients. Place of performance is Rochester, Minnesota. The order's ultimate completion date is June 30, 2021. Pricing is cost with no fee. Performance...

<p>The National Cancer Institute awarded a purchase order to Molecular Devices LLC for $7,821.75 on March 14, 2019, with an ultimate completion date of March 14, 2020. The order is firm fixed price with no set-aside designation. Place of performance is Gaithersburg, Maryland. The purchase order was issued to de-obligate funds from FY2019 expiring lines in accordance with NIH Office of Administrative Law and Management communication.</p>

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic for $23,550.00 on September 1, 2017, for subtype classification and harmonization of lymphoid malignancies. Performance is located in Rochester, Minnesota, with an ultimate completion date of August 31, 2018. The order is firm fixed-price with no set-aside designation.</p>

Mayo Clinic was awarded a cost-plus-fixed-fee delivery order against its indefinite delivery/indefinite quantity contract with the National Cancer Institute. The $1,996,069 order has a period of performance through July 2023 to support preclinical pharmacokinetic evaluations for the National Cancer Institute's Experimental Therapeutics program in Rochester, Minnesota. No set-aside designation was used for this order to further the agency's aim of aiding the development and approval of new cancer...

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic on September 17, 2018, for $15,000 to obtain follow-up procedure and outcome information data from 1,000 women evaluated for abnormal uterine bleeding at Mayo Clinic. The order carries firm fixed-price pricing with no set-aside designation. Place of performance is Bethesda, Maryland. The ultimate completion date is September 16, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic for $70,000 on September 22, 2017, for procurement of biosamples for analysis of suspected endometrial cancer and precursors. The order is firm fixed price with no set-aside designation. Performance occurs in Rochester, Minnesota, and the order completion date is September 21, 2018.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $218,370.00 firm fixed-price delivery order contract to Mayo Clinic, a large non-profit academic medical center, for &quot;Pharmacokinetic Studies with Selected Anticancer Compounds in NSG Mice.&quot; The period of performance is September 13, 2019 through September 12, 2024. This delivery order is issued under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients...

This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center. The contract, with a ceiling value of $76,500.00, supports the NCI's Cancer Genome Atlas (TCGA) program by providing tissue samples and data from various types of cancer. This order is part of a larger $9.9 million indefinite delivery/indefinite quantity (IDIQ) contract awarded to Mayo Clinic in 2021, which enables the NCI to procure research and...

This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mayo Clinic, a renowned non-profit academic medical center. The contract is for $1,603.00 and covers pre-clinical pharmacokinetic and pharmacology evaluations of cancer therapeutic agents being developed under the NCI's Experimental Therapeutics program. This work supports the transition of promising cancer treatments from the laboratory to early...